DaVita (DVA)
(Delayed Data from NYSE)
$138.57 USD
-2.88 (-2.04%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $138.52 -0.05 (-0.04%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.57 USD
-2.88 (-2.04%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $138.52 -0.05 (-0.04%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
New Strong Sell Stocks for February 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Stock Market News For Feb 14, 2019
by Zacks Equity Research
Wall Street rally continued in Wednesday buoyed by positive developments on the trade war front.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
DaVita HealthCare (DVA) Tops Q4 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 1.12% and -5.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
DaVita HealthCare (DVA) Down 11.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Falling Estimates & Price Mean for DaVita (DVA)
by Zacks Equity Research
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.
DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.
DaVita HealthCare (DVA) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -37.08% and -2.47%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) likely to gain from its Kidney Care wing. However, DaVita RX and GranuFlo units are likely to disappoint.
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
by Zacks Equity Research
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
5 Low Price-to-Book Stocks to Buy in a Volatile Market
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
by Zacks Equity Research
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
5 Dirt-Cheap PEG Stocks That Value Investors Love
by Zacks Equity Research
For investors looking to escape value traps, it is vital to determine where the stock is headed in the next 12 to 24 months.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?